ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. This list will be updated with the posting of errata reports on www.usp.org/USPNF/newOfficialText. This information will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

Page Number	Title	Section	Description
USP35–NF30			
1069	*Acid Stannous Chloride TS, Stronger*	TEST SOLUTIONS (TS)	Line 1: Change "See *Stannous Chloride, Acid, TS.*" to: See *Stannous Chloride, Acid, Stronger, TS.*
1699	*Ammonium Sulfate*	IMPURITIES *Limit of Nitrate*	Line 2 of *Control solution*: Change "ammonium nitrate" to: ammonium sulfate
1920	*Polysorbate 80*	SPECIFIC TESTS *Fats and Fixed Oils, Acid Value* ⟨401⟩	Line 4 of *Sample solution*: Change "phenolphthalein solution" to: phenolphthalein TS
		SPECIFIC TESTS *Fats and Fixed Oils, Hydroxyl Value* ⟨401⟩	Lines 13 and 14 of *Analysis*: Change "phenolphthalein solution" to: phenolphthalein TS
1960	*Sodium Stearyl Fumarate*	SPECIFIC TESTS *Fats and Fixed Oils, Saponification Value* ⟨401⟩	Line 12 of *Analysis*: Change "Result = $[(V_S - V_B) \times N \times F]/W$ V_S = volume of the *Titrant* consumed by the *Sample* (mL) V_B = volume of the *Titrant* consumed by the *Blank* (mL)" to: Result = $[(V_B - V_S) \times N \times F]/W$ V_B = volume of the *Titrant* consumed by the *Blank* (mL) V_S = volume of the *Titrant* consumed by the *Sample* (mL)
2539	*Cefdinir Capsules*	IMPURITIES *Organic Impurities*	Line 10 of *Analysis*: Change "C_U = concentration of the *Sample solution* (mg/mL)" to: C_U = nominal concentration of cefdinir in the *Sample solution* (mg/mL)
2664	*Cilostazol Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩ *Test 1*	Line 1 of *Standard solution*: Change "0.28 mg" to: 0.28 mg/mL
			Line 3 of *Standard solution*: Change "56 µg/mL" to: 5.6 µg/mL
			Line 4 of *Sample solution*: Change "56 µg/mL" to: 5.6 µg/mL
2798	*Cysteine Hydrochloride*	ASSAY	Line 4 of *Analysis*: Change "Insert the stopper, and allow to stand in the dark for 20 min." to: Insert the stopper, and allow to stand in the dark for 20 min, while remaining in the ice bath.

Page Number	Title	Section	Description
2994	*Drospirenone*	IMPURITIES *Organic Impurities, Procedure 2*	Line 1 of *Relative standard deviation*: Change "NMT 2.0%" to: NMT 15.0%
3037	*Enalaprilat Injection*	*Benzyl alcohol content (if present)*	Line 2 of *Standard solution*: Change "*Buffer solution*" to: *Mobile phase*
3048	*Entacapone Tablets*	IDENTIFICATION *A. Infrared Absorption* ⟨197K⟩	Line 3: Change "at about 2216, 1628, 1604, 1544, 1512, 1440, 1376, 1348, 1296, 1280, and 1208 cm^{-1}" to: at about 1628, 1604, 1544, 1512, 1440, 1376, 1348, 1296, 1280, and 1208 cm^{-1}
3632	*Lamivudine*	IMPURITIES *Organic Impurities, Other Related Compounds*	Columns 1–3, row 4 of *Table 1*, above *Salicylic acid*: Add "Lamivudine 1.0 —"
			Column 2, row 5 of *Table 1* for *Salicylic acid*: Change "1.0" to: 2.7
3700	*Lithium Carbonate Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Before *Analysis*: Add "*Spectrometric conditions* *Mode*: Flame photometer *Analytical Wavelength*: About 671 nm [NOTE— Adjust the instrument with the surfactant solution.]"
3751	*Magnesium Oxide*	SPECIFIC TESTS *Bulk Density and Tapped Density, Method I* ⟨616⟩	Line 1: Change "*Bulk Density and Tapped Density, Method I* ⟨616⟩:" to: *Bulk Density and Tapped Density of Powders, Bulk Density, Method I* ⟨616⟩:
3926	*Minocycline Hydrochloride*	IMPURITIES *Organic Impurities*	Line 2 of *Procedure*: Change "*Mobile phase* and *System suitability solution*: Proceed as directed in the *Assay* [NOTE—Protect the *Sample solutions* from light, store in a refrigerator, and use within 3 h.]" to: *Mobile phase, Standard solution, System suitability solution, Chromatographic system,* and *System suitability*: Proceed as directed in the *Assay*. [NOTE—Protect the *Standard solution* and the *Sample solutions* from light, store in a refrigerator, and use within 3 h.]
			Line 12 of *Procedure*: Delete "*Chromatographic system*—Proceed as directed in the *Assay*."
4167	*Oxybutynin Chloride Extended-Release Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩, *Test 1*	Line 2 of *Standard stock solutions*: Change "USP Oxybutynin RS" to: USP Oxybutynin Chloride RS
4210	*Pantoprazole Sodium*	*USP Reference standards*	Line 6 of *USP Pantoprazole Related Compound D and F Mixture RS*: Change "398.40" to: 397.40
4638	*Simethicone Emulsion*	IMPURITIES *Inorganic Impurities, Heavy Metals*	Line 1 of *Sample solution*: Change "1.0 g of simethicone from Emulsion" to: 1.0 g of Simethicone Emulsion
4779	*Telmisartan Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Under "Result = $(A_U \times C_S \times V \times 100)/(A_S \times D \times L)$": Add "$A_S$ = absorbance of the *Standard solution*"

Page Number	Title	Section	Description
4915	*Travoprost*	*Related compounds*	Column 4, row 4 (15-*epi* Diastereomer[2]) of *Table 1*: Change "0" to: 0.1
			Column 4, row 5 (5,6-*trans* Isomer[3]) of *Table 1*: Change "3" to: 3.5
5020	*Vinblastine Sulfate*	IMPURITIES *Organic Impurities*	Line 1: Change "*Mobile phase, System suitability solution,* and *System suitability*: Proceed as directed in the *Assay*." to: *Mobile phase, Standard solution, System suitability solution,* and *System suitability*: Proceed as directed in the *Assay*.
			Line 1 of *Injection size*: Change "200 µL" to: 200 µL (20 µL for *System suitability*)
Revision Bulletin, Official May 1, 2012			
Online	*Losartan Potassium Tablets*	IMPURITIES *Organic Impurities*	Line 2 of footnote *c* of *Table 4*: Change "Disregard peaks equal to or ●less● (RB 1-May-2012) than 0.1%." to: Disregard peaks ●less● (RB 1-May-2012) than 0.1%.
First Supplement to USP35–NF30			
5488	*Famotidine*	IMPURITIES *Organic Impurities*	Line 10: Change "*Standard solution*: 0.5 µg/mL of USP Famotidine RS in *Solution A* *System suitability stock solution*: 0.25 mg/mL of USP Famotidine Related Compound D RS in methanol *System suitability solution*: Transfer 1 mL of the *System suitability stock solution* and 0.5 mL of the *Standard solution* into a 100-mL volumetric flask, and dilute with *Solution A* to volume." to: *Standard stock solution*: 0.5 mg/mL of USP Famotidine RS in *Solution A* *Standard solution*: 0.5 µg/mL of USP Famotidine RS in *Solution A* *System suitability stock solution*: 0.25 mg/mL of USP Famotidine Related Compound D RS in methanol *System suitability solution*: Transfer 1 mL of the *System suitability stock solution* and 0.5 mL of the *Standard stock solution* into a 100-mL volumetric flask, and dilute with *Solution A* to volume.
Second Supplement to USP35–NF30			
5938	*Duloxetine Hydrochloride*	IDENTIFICATION *A. Infrared Absorption* ⟨197K⟩	Line 1: Change "*A. Infrared Absorption* ⟨197K⟩ *Sample solution*: 5 mg/mL in methanol *Acceptance criteria*: Meets the requirements" to: *A. Infrared Absorption* ⟨197K⟩
		C. Identification Tests—General, Chloride ⟨191⟩	Line 1: Change "*C. Identification Tests—General, Chloride* ⟨191⟩: Meets the requirements" to: *C. Identification Tests—General, Chloride* ⟨191⟩ *Sample solution*: 5 mg/mL in methanol *Acceptance criteria*: Meets the requirements